The development of new medical breakthroughs depends on the patients who volunteer to participate in clinical trials, but according to the Center for Information and Study on Clinical Research Participation, only 6 percent of clinical trials are completed on time and half of clinical research sites enroll one or no patients in their study.
Most Recent Posts
This week we focused on the role of patients within the R&D process, from discovery to market access.
You could have heard a pin drop as onetime clinical trial participant Laura Hull spoke at yesterday's "Research in Your Backyard" event in Winston-Salem, N.C. More than a few eyes had tears in them.
The recent spotlight on prescription drug abuse has overshadowed an important patient population that must deal with chronic pain everyday. Addicts, overdoses and mentions of the “opioid epidemic” in the media has made is increasingly difficult for the people who depend on these medicines to be able to get them.
Each patient is unique, which means that medicines and therapies often need to be tailored to fit individual needs to ensure the best possible care. While the research and development (R&D) pipeline holds the promise of new, innovative treatments for those suffering from a variety of diseases, it is important to explore all options to improve patient health.
A patient should never have to worry about the safety of their medicines. Unfortunately, patient’s lives are put at risk across the country due to counterfeit, substandard, or otherwise unsafe medicines.
Since taking effect in 2006, Medicare Part D has provided seniors with critical access to the prescription medications they need. As part of the program, patients have broader access to medicines that fall into one of six “protected classes” that include anticonvulsants, antidepressants, antineoplastics, antipsychotics, antiretrovirals and immunosuppressants.
This post originally appeared on the Age of Personalized Medicine.
Since the Accelerating Medicines Partnership (AMP) was announced last month, there’s been robust discussion throughout the scientific community and the general public about the goals of this unique partnership between the National Institutes of Health (NIH), several non-profit disease foundations, 10 biopharmaceutical compani
Patients, physicians, biopharmaceutical companies, and the federal government all want the same thing: New treatment options to save lives from diseases that claim far too many.
The Sunshine Act encourages transparency around the interactions between physicians and biopharmaceutical professionals. These conversations are vital to improving patient care.
We revisit the research and development (R&D) pipeline quite a bit, because it is a crucially important aspect of modern medicine. Having recently released our Medicines in Development report on the 180 medicines in the pipeline to treat diabetes and related conditions, it is important to recognize the steps that fuel innovation and medical advances.
By 2020, nearly half of all Americans will have at least one chronic condition. As more and more people are afflicted by chronic disease, it is increasingly important to develop new ways to prevent, manage, and treat these life-altering conditions.
The existing model of bringing new medicines to patients is a costly, exhaustive, and thorough process. In fact, to develop a new medicine under the federal process takes about $1 billion and 10 years — with a failure rate of roughly 99 percent.
Developing new medicines is a lengthy and complex process, relying heavily on volunteer participation to evaluate potential therapies for safety and effectiveness in clinical trials. Without the patients who volunteer to participate in clinical research, the development of new treatments would not be possible.
Challenges in Patient Recruitment